IHS Chemical Week

Regions :: North America :: U.S.

Lonza and BioWa sign license agreements with Pfizer

7:30 AM MDT | July 30, 2013 | Deepti Ramesh

Lonza and BioWa (La Jolla, CA), a wholly owned subsidiary of biopharmaceutical company Kyowa Hakko Kirin (Tokyo), have entered into research agreements with Pfizer allowing the use of the Potelligent CHOK1SV cell line in the R&D of multiple proprietary antibodies in Pfizer’s pipeline, Lonza says. Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies. The cell line combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System. The GS system includes Lonza’s...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily newsvv and analysis from the entire global chemical enterprise on chemweek.com
  • Free mobile edition of Chemical Week
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional focus
  • Global outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa